Understanding how NF1 and SPRED1 loss affects melanoma
Defining the role of NF1 and SPRED1 loss in melanoma
This study is looking at how changes in certain genes, NF1 and SPRED1, might affect the growth of melanoma and how well treatments work, so that patients can better understand how their unique genetics could influence their care and outcomes.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10978162 on NIH RePORTER |
What this research studies
This research investigates the role of NF1 and SPRED1 genes in melanoma, particularly focusing on how their loss contributes to cancer progression and treatment resistance. By analyzing mutations in these genes, the study aims to identify additional genetic alterations that may enhance melanoma's aggressiveness and impact responses to therapies. Patients may benefit from insights into how their specific genetic makeup influences treatment options and outcomes. The research employs both laboratory experiments and clinical data to explore these relationships.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acral lentiginous melanoma, particularly those with known mutations in NF1 or SPRED1.
Not a fit: Patients with melanoma that does not involve NF1 or SPRED1 mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment strategies for melanoma patients by identifying specific genetic factors that influence therapy response.
How similar studies have performed: Previous research has shown promising results in understanding the genetic underpinnings of melanoma, suggesting that this approach could yield valuable insights.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Yeh, Iwei — University of California, San Francisco
- Study coordinator: Yeh, Iwei
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.